Abstract
Low expression of human leukocyte antigen (HLA) class I in human tumors may be related to defects of the antigen-processing machinery (APM) components. Neuroblastoma cells are virtually HLA class I negative, but (i) the underlying mechanisms are unknown, and (ii) expression of the APM components has never been investigated. Here we have used a panel of novel monoclonal antibodies to proteasomal and immunoproteasomal components, chaperons and transporter associated with antigen processing (TAP) to characterize 24 stroma-poor neuroblastoma tumors and six neuroblastoma cell lines. Primary tumors showed defects in the expression of zeta, tapasin, TAP1 or TAP2, HLA class I heavy chain and β2 microglobulin, LMP2 and LMP7, as compared to normal adrenal medulla. Neuroblastoma cell lines displayed roughly similar patterns of APM expression in comparison to primary tumors. Incubation of neuroblastoma cell lines with interferon-γ caused upregulation of HLA class I molecules and reduced lysis by killer inhibitory receptor HLA ligand-matched NK cells. Defects in APM components explain reduced peptide loading on HLA class I molecules, their instability and failure to be expressed on the cell surface. HLA class I upregulation by interferon-γ, although enhancing neuroblastoma cell recognition by cytotoxic T cells, dampens their susceptibility to NK cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Airoldi I, Meazza R, Croce M, Di Carlo E, Piazza T, Cocco C, D'Antuono T, Pistoia V, Ferrini S and Corrias MV . (2004). Br. J. Cancer, 90, 2210–2218.
Brodeur GM . (2003). Nat. Rev. Cancer, 3, 203–216.
Brodeur GM, Seeger RC, Barrett A, Berthold F, Castleberry RP, D'Angio G, De Bernardi B, Evans AE, Favrot M and Freeman AI . (1988). J. Clin. Oncol., 6, 1874–1881.
Corrias MV, Occhino M, Croce M, De Ambrosis A, Pistillo MP, Bocca P, Pistoia V and Ferrini S . (2001). Tissue Antigens, 57, 110–117.
Desai SA, Wang X, Noronha EJ, Zhou Q, Rebmann V, Grosse-Wilde H, Moy FJ, Powers R and Ferrone S . (2000). J. Immunol., 165, 3275–3283.
Facchetti P, Prigione I, Ghiotto F, Tasso P, Garaventa A and Pistoia V . (1996). Cancer Immunol. Immunother., 42, 170–178.
Facchetti P, Tacchetti C, Prigione I, Airoldi I, Favre A, Grossi CE and Pistoia V . (1999). Exp. Cell Res., 253, 440–453.
Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, Lopez-Botet M, Duggan-Keen M and Stern PL . (1997). Immunol. Today, 18, 89–95.
Groettrup M, Soza A, Kuckelkorn U and Kloetzel PM . (1996). Immunol. Today, 17, 429–435.
Hedley DW, Friedlander ML and Taylor IW . (1985). Cytometry, 6, 327–333.
Hochstrasser M . (1996). Annu. Rev. Genet., 30, 405–439.
Kageshita T, Hirai S, Ono T, Hicklin DJ and Ferrone S . (1999). Am. J. Pathol., 154, 745–754.
Kishore R, Hicklin DJ, Dellaratta DV, Golde U, Kageshita T, Seliger B and Ferrone S . (1998). Tissue Antigens, 51, 129–140.
Lampson LA and Fisher CA . (1984). Proc. Natl. Acad. Sci. USA, 81, 6476–6480.
Lampson LA, Fisher CA and Whelan JP . (1983). J. Immunol., 130, 2471–2478.
Lampson LA and George DL . (1986). J. Interferon Res., 6, 257–265.
Marozzi A, Meneveri R, Bunone G, De Santis C, Lopalco L, Beretta A, Agresti A, Siccardi AG, Della Valle G and Ginelli E . (1993). Scand. J. Immunol., 37, 661–667.
Moretta A, Bottino C, Vitale M, Pende D, Biassoni R, Mingari MC and Moretta L . (1996). Annu. Rev. Immunol., 14, 619–648.
Neal ZC, Imboden M, Rakhmilevich AL, Kim KM, Hank JA, Surfus J, Dixon JR, Lode HN, Reisfeld RA, Gillies SD and Sondel PM . (2004). Cancer Immunol. Immunother., 53, 41–52.
Ogino T, Wang X and Ferrone S . (2003a). J. Immunol. Methods, 278, 33–44.
Ogino T, Wang X, Kato S, Miyokawa N, Harabuchi Y and Ferrone S . (2003b). Tissue Antigens, 62, 385–393.
Olerup O and Zetterquist H . (1992). Tissue Antigens, 39, 225–235.
Passoni L, Scardino A, Bertazzoli C, Gallo B, Coluccia AM, Lemonnier FA, Kosmatopoulos K and Gambacorti-Passerini C . (2002). Blood, 99, 2100–2106.
Pickl WF, Majdic O, Fae I, Reuschel R, Holter W and Knapp W . (1993). J. Immunol., 151, 2613–2622.
Pinkel D, Straume T and Gray JW . (1986). Proc. Natl. Acad. Sci. USA, 83, 2934–2938.
Ponzoni M, Guarnaccia F, Corrias MV and Cornaglia-Ferraris P . (1993). Int. J. Cancer, 55, 817–823.
Puppo F, Bignardi D, Contini P, Hamby CV, Brenci S, Lanza L, Ghio M, Scudeletti M, Indiveri F and Ferrone S . (1999). Tissue Antigens, 53, 253–262.
Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF and Velardi A . (2002). Science, 295, 2097–2100.
Sarkar AK and Nuchtern JG . (2000). Cancer Res., 60, 1908–1913.
Seliger B, Cabrera T, Garrido F and Ferrone S . (2002). Semin. Cancer Biol., 12, 3–13.
Seliger B, Maeurer MJ and Ferrone S . (2000). Immunol. Today, 21, 455–464.
Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV and Roald B . (1999a). Cancer, 86, 349–363.
Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B, Stram DO, Gerbing RB, Lukens JN, Matthay KK and Castleberry RP . (1999b). Cancer, 86, 364–372.
Stam NJ, Spits H and Ploegh HL . (1986). J. Immunol., 137, 2299–2306.
Tanaka K and Kasahara M . (1998). Immunol. Rev., 163, 161–176.
Temponi M, Kekish U, Hamby CV, Nielsen H, Marboe CC and Ferrone S . (1993). J. Immunol. Methods, 161, 239–256.
Thiele CJ . (1999). Neuroblastoma Palsson JRWMaB (ed). Hluwer Academic Publishers: Great Britain, pp. 21–53.
Tonini GP, Boni L, Pession A, Rogers D, Iolascon A, Basso G, Cordero di Montezemolo L, Casale F, Perri P, Mazzocco K, Scaruffi P, Lo Cunsolo C, Marchese N, Milanaccio C, Conte M, Bruzzi P and De Bernardi B . (1997). J. Clin. Oncol., 15, 85–93.
Vertuani S, De Geer A, Levitsky V, Kogner P, Kiessling R and Levitskaya J . (2003). Cancer Res., 63, 8006–8013.
Watanabe Y, Kuribayashi K, Miyatake S, Nishihara K, Nakayama E, Taniyama T and Sakata T . (1989). Proc. Natl. Acad. Sci. USA, 86, 9456–9460.
Weiss WA, Aldape K, Mohapatra G, Feuerstein BG and Bishop JM . (1997). EMBO J., 16, 2985–2995.
Williams AP, Peh CA, Purcell AW, McCluskey J and Elliott T . (2002). Immunity, 16, 509–520.
Wolfl M, Jungbluth AA, Garrido F, Cabrera T, Meyen-Southard S, Spitz R, Ernestus K and Berthold F . (2005). Cancer Immunol. Immunother., 54, 400–406.
Zarling AL, Luckey CJ, Marto JA, White FM, Brame CJ, Evans AM, Lehner PJ, Cresswell P, Shabanowitz J, Hunt DF and Engelhard VH . (2003). J. Immunol., 171, 5287–5295.
Zinkernagel RM and Doherty PC . (1974). Nature, 248, 701–702.
Acknowledgements
We thank Mr Federico Comanducci for the help in immunohistochemical studies, Dr Emil Bogenmann for the kind gift of the HTLA 230 cell line and Mrs Chiara Bernardini for the excellent secretarial assistance. We are deeply indebted to Dr Giorgio Parmiani for critical revision of the manuscript, criticism and suggestions. This work has been supported by grants from the Ministero della Salute (Ricerca Corrente and Ricerca Finalizzata), the Ministero dell'Università e della Ricerca, and the Compagnia di San Paolo to VP and by PHS Grant R01 CA 67108 awarded by the National Cancer Institute, DHHS to SF. LR was the recipient of a fellowship from Italian Ministry of University and Research.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Raffaghello, L., Prigione, I., Bocca, P. et al. Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implications. Oncogene 24, 4634–4644 (2005). https://doi.org/10.1038/sj.onc.1208594
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1208594
Keywords
This article is cited by
-
Model for predicting prognosis and immunotherapy based on CD+8 T cells infiltration in neuroblastoma
Journal of Cancer Research and Clinical Oncology (2023)
-
Immune characterization of pre-clinical murine models of neuroblastoma
Scientific Reports (2020)
-
Redirecting T cells to treat solid pediatric cancers
Cancer and Metastasis Reviews (2019)
-
Spontaneous regression of neuroblastoma
Cell and Tissue Research (2018)
-
Favorable NK cell activity after haploidentical hematopoietic stem cell transplantation in stage IV relapsed Ewing’s sarcoma patients
Bone Marrow Transplantation (2015)